Table 2.

Anti‐nuclear antibodies (ANA) immunofluorescence pattern and titre in breast lesion patients and controls (n = 182)

Immunofluorescence pattern	Malignant tumours n = 32/72	Benign tumours n = 3/19	Controls n = 5/91
Speckled  (fine dense)	10/32 (31·2%)	2/3 (66·6%)	2/5 (40·0%)
Speckled (fine)	9/32 (28·1%)	0	0
Speckled (coarse)	8/32 (25·0%)	1/3 (33·4%)	1/5 (20%)
Nucleolar	3/32 (9·4%)	0	0
Homogeneous	2/32 (6·2%)	0	0
Cytoplasmatic	0	0	2 (40·0%)
ANA titre	1/80–12/32 (37·5%)	All = 1 : 80	1:80–3/5 (60%)
	1/160–13/32 (40·6%)		1/160–1/5 (20%)
	1/320–5/32 (15·6%)		1/320–1/5 (20%)
	1/640–2/32 (6·2%)